NM_013254.4:c.40A>G
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4_StrongBS2_Supporting
The NM_013254.4(TBK1):c.40A>G(p.Ile14Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000062 in 1,613,842 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_013254.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TBK1 | NM_013254.4 | c.40A>G | p.Ile14Val | missense_variant | Exon 2 of 21 | ENST00000331710.10 | NP_037386.1 | |
TBK1 | XM_005268809.2 | c.40A>G | p.Ile14Val | missense_variant | Exon 2 of 21 | XP_005268866.1 | ||
TBK1 | XM_005268810.2 | c.40A>G | p.Ile14Val | missense_variant | Exon 2 of 21 | XP_005268867.1 | ||
TBK1 | XR_007063071.1 | n.139A>G | non_coding_transcript_exon_variant | Exon 2 of 18 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152160Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251158Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135748
GnomAD4 exome AF: 0.00000410 AC: 6AN: 1461682Hom.: 0 Cov.: 30 AF XY: 0.00000275 AC XY: 2AN XY: 727130
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152160Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74340
ClinVar
Submissions by phenotype
not specified Uncertain:1
Variant summary: TBK1 c.40A>G (p.Ile14Val) results in a conservative amino acid change located in the Protein kinase domain (IPR000719) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2e-05 in 251158 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.40A>G in individuals affected with Autoinflammation with arthritis and vasculitis has been reported. At least one publication reports experimental evidence evaluating an impact on protein function, with the variant showing no damaging effect on NFKB-induced luciferase activity compared to WT (e.g. vanderZee_2017). The following publication has been ascertained in the context of this evaluation (PMID: 28008748). ClinVar contains an entry for this variant (Variation ID: 475939). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 Uncertain:1
This sequence change replaces isoleucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 14 of the TBK1 protein (p.Ile14Val). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change does not substantially affect TBK1 function (PMID: 28008748). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt TBK1 protein function. ClinVar contains an entry for this variant (Variation ID: 475939). This variant has not been reported in the literature in individuals affected with TBK1-related conditions. This variant is present in population databases (rs781325780, gnomAD 0.007%). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at